High Throughput Screening

For Drug Screening and Compound Repurposing, the Fraunhofer ITMP has a focus on the development of biologically relevant and screening-compatible assays for use in biomedical research, chemical biology and drug discovery. An automated screening platform allows for the development of high-throughput in-vitro biochemical and cell-based assays for the major protein target classes based on optical, label-free and high-content imaging technologies. Several compound libraries are available for screening, including collections of up to 400,000 chemically diverse compounds, target class focused sets, natural products and compounds for drug repurposing. The latter consist of approved drugs in clinical use across many indications and preclinical compounds with varying levels of validation. A comprehensive IT infrastructure supporting these activities allows for the data-driven approach to select optimal compounds for hit-to-lead progression based on their mechanism of action, selectivity and ADMET studies.

Service offering:

• State-of-the-art in-vitro methods and technologies for innovative assay development.
• All common optical and label-free assay formats, as well as high-content imaging.
• Assay technologies: luminescence, fluorescence intensity, fluorescence resonance energy transfer (FRET/TR-FRET), AlphaScreen, fluoresence polarization, Microscale Thermophoresis (MST), high-content imaging (HC).
• Access to a wide range of compound libraries ready for screening.
• Annotation of screening hits using in-vitro mechanism of action, selectivity and ADMET profiling combined with data mining.
• Prioritisation of compounds using bioinformatics and chemoinformatics workflows to provide high quality compounds as a starting point for drug development.
• Expertise in progressing hits into lead compounds and clinical candidates.